The science

What NAD+ actually does inside a cell.

No hype, no borrowed jargon. Here is the biology behind the molecule, the pathways that depend on it, what the human evidence currently supports — and what it does not.

The basics

A coenzyme in every cell

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every living cell. It shuttles electrons during glycolysis, the citric acid cycle and oxidative phosphorylation — the three steps that convert food into ATP, the currency your cells spend.

Levels decline with age

Tissue measurements across skin, liver, muscle and brain suggest NAD+ availability falls substantially between early adulthood and later life. Chronic inflammation and higher activity of the NAD+-consuming enzyme CD38 are both implicated in that decline.

Consumed, not just used

Unlike a catalyst that is recycled indefinitely, NAD+ is cleaved and consumed by sirtuins, PARPs and CD38. Cells rebuild it continuously through the salvage pathway, which recycles nicotinamide back into NAD+ via the enzyme NAMPT.

The pathways

Four processes compete for the same molecule.

Sirtuins (SIRT1–SIRT7)

NAD+-dependent deacetylases involved in mitochondrial biogenesis, DNA-repair signalling and metabolic regulation. Without sufficient NAD+ they simply cannot act.

PARPs

Poly(ADP-ribose) polymerases detect and help repair DNA strand breaks. Repair work is NAD+-expensive, so heavy DNA damage draws down the cellular pool.

CD38

An immune-cell enzyme that degrades NAD+ precursors. Its activity rises with age-related inflammation, accelerating the decline.

The salvage pathway

The main route of resupply in humans: nicotinamide → NMN (via NAMPT) → NAD+ (via NMNAT). This is why precursor and direct-NAD+ strategies differ in how quickly they raise the pool.

The evidence

Mitochondrial function

In preclinical models, restoring NAD+ improved mitochondrial respiration and endurance capacity in aged muscle. Human trials are smaller, but consistently show that circulating NAD+ can be raised by supplementation.

Metabolic markers

Randomised human studies of NAD+ precursors report improved insulin sensitivity and muscle NAD+ content in some populations, with effect sizes that vary by age and baseline status.

What is not established

NAD+ is not a treatment for any disease and has not been shown to extend human lifespan. The honest summary is a strong mechanistic rationale, encouraging early human data, and ongoing trials.

This page is general information, not medical advice. NAD+ The One is a supplement and is not intended to diagnose, treat, cure or prevent any disease.

Common questions

Clinic protocols typically deliver 500–1000mg per session, spaced weekly, because the cellular pool refills over days rather than hours. A weekly 1000mg dose mirrors that cadence without a daily routine to maintain.
Precursors must pass the gut and liver and then be converted enzymatically, and much of an oral dose is metabolised before it reaches tissue. Delivering NAD+ directly bypasses first-pass metabolism.
Most people report changes in energy and sleep quality across the first three to six weeks. Cellular repair pathways work on a longer horizon than a stimulant does.
NAD+ is well tolerated in reported studies; flushing, mild nausea or transient site tenderness are the common complaints. Speak with your doctor before starting if you are pregnant, breastfeeding, undergoing cancer treatment or taking prescription medication.

One formula. Properly dosed.

Shop The One — £199